The Complete Guide to CPT Codes 11102–11107

Schedule Your Free Consultation

The Biopsy Billing Errors That Cost Dermatology Practices Thousands Every Month

Skin biopsies are the most frequently performed procedures in dermatology and they are among the most frequently miscoded. The introduction of CPT codes 11102 through 11107 in 2019 fundamentally changed how biopsies are billed, replacing the old single-code system with a technique-specific, add-on-enabled structure designed to more accurately capture reimbursement for multi-site encounters.

Five years later, many dermatology practices are still not using this code set correctly. Practices are billing a single code when three separate procedures occurred. They're missing add-on codes they're fully entitled to. They're failing to apply the correct modifier when two biopsy techniques are used on different lesions in the same visit. And they're leaving the documentation gaps that make every one of those errors a denial waiting to happen.

The financial consequence is immediate and compounding. A practice performing 25 biopsies per week that consistently misses one add-on code per encounter loses $75–$130 per visit $97,500 to $169,000 annually from a single, fixable billing error. This guide gives your team the complete picture: what each code means, when to use it, how to document it, and how to stop leaving biopsy revenue behind.

💡  Did You Know?

CPT codes 11102–11107 replaced the old 11100/11101 biopsy code set in 2019 yet many practices are still applying the old logic of billing one code for all biopsies regardless of technique. The new codes reward technique specificity and site-by-site coding, delivering significantly higher reimbursement when used correctly.

The add-on codes 11103, 11105, and 11107 are exempt from NCCI bundling edits by definition meaning they do not require Modifier 59 when billed with their parent code. However, when two primary codes from this family are billed together, a modifier IS required.

Approximately 40% of multi-biopsy encounters in dermatology are coded as a single primary biopsy a systematic undercoding pattern that typically represents the practice's single largest per-procedure revenue gap.

What Are CPT Codes 11102–11107 — And What Exactly Do They Represent?

The 11102–11107 code set was built around a technique-first billing philosophy: the method used to obtain the tissue sample determines which code is appropriate, not just the size of the lesion or the number of specimens. Understanding this distinction is the foundation of accurate biopsy billing.

11102 — Tangential Biopsy, First Lesion (Primary Code)

Tangential biopsies are performed by removing tissue parallel to the skin surface without full-thickness penetration of the dermis. Common techniques include shave biopsies, saucerization, and scoop excisions. This is the go-to technique for superficial lesions where deep dermal tissue is not required for diagnosis.

When to use 11102: Suspected actinic keratoses, seborrheic keratoses, superficial pigmented lesions, flat or slightly elevated nevi, and early basal cell carcinoma presentations where a surface sample is clinically adequate.

11103 — Tangential Biopsy, Each Additional Lesion (Add-On Code)

11103 is the add-on code for each additional tangential biopsy beyond the first performed in the same clinical session. It is always billed alongside 11102 as the parent code never standalone. No modifier is required on 11103 when paired with 11102.

Billing rule: 3 tangential biopsies in one visit = 11102 + 11103 + 11103 (or 11102 + 11103 ×2). Each additional lesion adds reimbursement without a separate primary code or modifier requirement.

11104 — Punch Biopsy, First Lesion (Primary Code)

Punch biopsies use a circular cutting tool to obtain a full-thickness cylindrical core sample penetrating through the epidermis and dermis into subcutaneous tissue. This technique is required when deeper tissue layers must be assessed for accurate diagnosis.

When to use 11104: Suspicious melanocytic lesions, inflammatory dermatoses (psoriasis, lichen planus, eczema confirmation), connective tissue disorders, suspected melanoma where depth assessment matters, and lesions requiring full-thickness histopathological evaluation.

11105 — Punch Biopsy, Each Additional Lesion (Add-On Code)

11105 is the add-on for each additional punch biopsy at a distinct anatomical site in the same session. When two punch biopsies are performed at different locations on the body, 11104 (primary) + 11105 (add-on with Modifier XS or 59) is the correct code combination.

Critical modifier rule: Unlike 11103 when paired with 11102, 11105 requires Modifier XS or 59 when the sites are distinct anatomical structures because payers need documentation that confirms these are separate, independently billable services.

11106 — Incisional Biopsy, First Lesion (Primary Code)

Incisional biopsies involve partial removal of a lesion using a blade deeper than a punch, but not a complete excision. This technique is used when the diagnosis requires a larger, deeper tissue sample that a punch biopsy cannot adequately provide.

When to use 11106: Deep soft tissue tumors, larger lesions requiring partial sampling for diagnosis, suspected lymphoma or lymphoid infiltrates, panniculitis, fasciitis, and conditions requiring assessment of deep dermal or subcutaneous architecture.

11107 — Incisional Biopsy, Each Additional Lesion (Add-On Code)

11107 is the add-on for each additional incisional biopsy at a distinct site. It follows the same modifier rules as 11105 Modifier XS or 59 required when the sites are anatomically distinct and requires the most rigorous documentation of all biopsy add-on codes due to the invasive nature of the technique.

📊 CPT 11102–11107: Complete Biopsy Code Reference Table

Here is the complete at-a-glance reference for every code in the biopsy family with clinical guidance, reimbursement ranges, and dermatology-specific applications:

🩺 Dermatology-Specific Biopsy Coding Scenarios — Real-World Application

Scenario 1: Single Suspicious Mole on the Arm

A new patient presents with a changing pigmented lesion on the left upper arm. The dermatologist performs a punch biopsy to obtain a full-thickness sample for pathology. Code: 11104 only. One lesion, one technique, one site. Straightforward. Add ICD-10 for uncertain behavior of melanocytic lesion.

Scenario 2: Three Actinic Keratoses Biopsied Tangentially at Separate Sites

During a full skin exam, the dermatologist identifies three distinct actinic keratoses on the scalp, right forearm, and left cheek. All three are biopsied using a shave technique. Code: 11102 + 11103 + 11103 (or 11102 + 11103 ×2). No modifiers required on add-on codes. Document each site specifically in the clinical note.

Scenario 3: Punch Biopsy + Tangential Biopsy — Different Lesions, Same Visit

A patient has a suspicious pigmented lesion on the back (punch biopsy performed) and a flat AK on the nose (tangential shave biopsy performed). Two different techniques, two different anatomical sites. Code: 11104 (punch, back) + 11102 with Modifier XS (tangential, nose). Both are primary codes modifier required on the lower-value secondary code. Document both sites with distinct lesion descriptions and clinical rationale for each technique choice.

Scenario 4: Two Punch Biopsies, Same Anatomical Region — One Site Each

A patient presents with two separate suspicious lesions one on the right lateral neck and one on the left lateral neck. Both are biopsied with a punch tool. Code: 11104 + 11105 with Modifier XS. Clinical note must clearly document each lesion at a distinct location. 'Right lateral neck at the hairline' and 'left lateral neck, mid-cervical' is sufficient. 'Bilateral neck' is not insufficient site specificity creates denial risk.

Scenario 5: Incisional Biopsy for Deep Inflammatory Lesion + Punch for Separate Lesion

A patient presents with a deep, indurated nodule on the thigh (incisional biopsy to rule out panniculitis) and a separate changing mole on the shoulder (punch biopsy for melanoma workup). Code: 11106 (incisional, thigh) + 11104 with Modifier XS (punch, shoulder). Document clinical rationale for selecting incisional technique on the nodule explain why punch was insufficient for diagnosis. Both primary codes billed with modifier on secondary.

📊 Biopsy Code Pairing & Modifier Quick-Reference Guide

Understanding which modifier applies and when is the single most critical factor in preventing multi-biopsy claim denials. Here is the complete code pairing reference for every common biopsy combination:

⚠️  Critical Modifier Rule — Add-On Codes vs Primary Code Combinations

Add-on codes (11103, 11105, 11107) never require modifiers when billed with their designated parent code. They are NCCI-exempt by definition and are automatically paid when the parent code is present on the claim.

When two different PRIMARY codes from the 11102–11107 family are billed on the same claim (e.g., 11102 + 11104, or 11104 + 11106), Modifier XS or 59 is required on the secondary code to override NCCI bundling edits. Without the modifier, the secondary code will be automatically denied.

🧾 Documentation Requirements for CPT 11102–11107 — 2026 Compliance Checklist

Biopsy billing without airtight documentation is not compliant billing it's a claim waiting to be denied or reversed in audit. Every biopsy code submitted must be independently supported by the clinical record. Here is the documentation standard your practice must meet:

🧾  Biopsy Documentation Compliance Checklist — MedCloudMD 2026 Standard

✔  Anatomical Location — Specific and Precise: Document the exact anatomical location of each lesion biopsied ('right posterior shoulder, mid-scapular region' — not 'shoulder' or 'back'). Site specificity is what justifies multiple codes and modifiers.

✔  Biopsy Technique Documented for Each Lesion: Specify the technique used — shave/tangential, punch, or incisional — for every lesion. The technique drives the CPT code selection and must match the code submitted.

✔  Lesion Description and Clinical Characteristics: Document size, morphology, color, border regularity, surface features, and any suspicious characteristics. Clinical description supports medical necessity and justifies the biopsy decision.

✔  Medical Necessity Established for Each Biopsy: State the clinical reason for performing the biopsy — 'changing mole with asymmetry and irregular border — biopsy to rule out melanoma' is a medical necessity statement. 'Biopsy performed' is not.

✔  Number of Lesions Biopsied Documented: Clearly state the total number of biopsies performed and the technique for each. 'Three tangential biopsies performed on separate lesions' with site-specific documentation for each supports 11102 + 11103 ×2.

✔  Distinct Site Documentation for Multi-Site Claims: When two or more biopsies are performed at different sites and modifiers are used, each site must be explicitly named in the note with its own clinical description and rationale.

✔  Pathology Specimen Submission Documented: Note the number of specimens submitted, the lab they were sent to, and the specimen type. Pathology coordination documentation is required for complete biopsy billing support.

✔  Clinical Rationale for Technique Choice: When incisional technique is used (11106/11107), document why incisional was chosen over punch — 'lesion size and depth require larger tissue core for adequate histopathological assessment'.

✔  Correct ICD-10 Code Linked to Each Biopsy Site: Each lesion biopsied must have a corresponding diagnosis code that reflects its clinical presentation. Mismatched or absent diagnosis codes generate automatic claim denials.

✔  Modifier Justified by Documentation: When Modifier XS or 59 is applied, the note must independently establish the distinct anatomical site — the modifier is only defensible when the documentation supports it without any ambiguity.

✔  Provider Signature and Date: All documentation must be signed and dated by the performing provider on the date of service. Unsigned or undated notes are non-billable in any audit context.

💰 Reimbursement & Revenue Optimization — Multi-Biopsy Encounter Analysis

Here is what the revenue difference looks like between correctly coded multi-biopsy encounters and systematic undercoding across the most common clinical scenarios in dermatology practice:

📈  Annual Revenue Impact — The Real Cost of Missing Add-On Codes

A dermatology practice performing 30 multi-biopsy encounters per week where at least one add-on code is missed per encounter loses an average of $90 per visit × 30 visits × 50 weeks = $135,000 annually in uncollected biopsy revenue. That is legitimate reimbursement for clinical work already performed — recoverable immediately with correct coding.

📈 Undercoding Revenue Loss — Scenario-by-Scenario Breakdown

Here is the direct financial cost of the most common biopsy undercoding patterns showing exactly what's being lost and why:

Scenario	Codes Billed (Undercoded)	Revenue Collected	Revenue Entitled	Revenue Lost Per Encounter
2 AK biopsies — bills only 11102	11102 only	$110	$185	$75 lost — 11103 never submitted
3 punch biopsies — bills only 11104	11104 only	$155	$365	$210 lost — 11105 ×2 never submitted
Punch + tangential — bills only 11104	11104 only	$155	$265	$110 lost — 11102 with XS never submitted
2 incisional — bills only 11106	11106 only	$190	$355	$165 lost — 11107 never submitted
3-site mixed biopsy — 1 code only	11104 only	$155	$470	$315 lost — add-ons + second primary missed

🚫 Common Biopsy Billing Mistakes That Trigger Denials and Revenue Loss

🚫  The Coding Errors Your Practice Cannot Afford to Keep Making

Billing Only the Primary Code on Multi-Biopsy Encounters: The most widespread and costly biopsy billing error. When three tangential biopsies are performed but only 11102 is submitted, two-thirds of the potential reimbursement is permanently lost. Add-on codes must be actively applied — they are not automatic.

Confusing Primary and Add-On Code Rules: Billing 11103 without 11102, or 11105 without 11104, generates an automatic claim rejection — add-on codes cannot stand alone. Equally, billing 11104 + 11105 without a modifier when both are considered at distinct sites creates a denial. The rules differ by code pairing type.

Missing Modifier on Same-Day Different-Technique Biopsies: When both 11102 and 11104 are performed in the same session (tangential and punch on different lesions), a modifier is required on the secondary code. Omitting it means the secondary claim is bundled and denied — silently and permanently.

Vague Anatomical Site Documentation: 'Lesion on the back' does not support two separate biopsy codes. 'Right posterior shoulder at the superior border of the scapula' and 'left lumbar region, 3 cm lateral to midline' do. Specificity is what separates a defensible claim from an automatic denial.

Incorrect Technique-to-Code Mapping: Billing 11104 (punch) for a procedure that was actually performed as a shave (tangential) is a coding error — regardless of intent. The code submitted must match the technique documented. Mismatches create both denial risk and compliance exposure in audit.

Failing to Submit Pathology Coordination Documentation: Some payers require evidence of specimen submission as part of biopsy claim validation. Practices that do not document specimen submission details and lab information create unnecessary denial vulnerability.

Not Appealing Biopsy Denials: Many biopsy denials — particularly those involving modifier disputes or site documentation — are successfully reversed on appeal when supported by complete clinical notes. Accepting biopsy denials without appeal is accepting permanent revenue loss that is frequently recoverable.

✅ Pro Tips to Maximize Biopsy Revenue in Your Dermatology Practice

✅  Expert Strategies From the MedCloudMD Biopsy Coding Team

Create a Biopsy Procedure Note Template That Drives Code Accuracy: Build a structured template into your EHR that prompts providers to document technique, site-specific anatomical location, lesion description, and medical necessity for each biopsy. A template that captures these elements automatically eliminates the most common documentation gaps.

Count Lesions at the Time of Procedure — Not at Billing: The number of lesions biopsied drives code and add-on selection. Establishing a practice workflow where providers log each biopsy with technique and site during the encounter — not reconstructed from memory at billing — dramatically improves accuracy and prevents missed add-ons.

Use XS as Your Default Modifier for Different-Site Biopsies — Medicare: For Medicare and Medicare Advantage claims, Modifier XS (Separate Structure) is more specific and preferred over Modifier 59 when biopsies are performed on anatomically distinct structures. Using XS also reduces your statistical Modifier 59 usage profile — which lowers RAC audit flag risk.

Verify Payer-Specific Biopsy Modifier Preferences Before Every Submission: Commercial payers often have specific modifier preferences that differ from Medicare guidance. Blue Cross, Aetna, Cigna, and UHC each have distinct policies on modifier use for biopsy code pairs. A current payer modifier matrix prevents systematic modifier-related denials.

Train Providers to Document Technique Choice Rationale for Incisional Biopsies: 11106 and 11107 require the most documentation support of any biopsy code. A one-sentence clinical rationale for why incisional technique was chosen over punch — 'lesion depth and clinical presentation required larger tissue core for accurate assessment' — makes the claim audit-defensible.

Conduct a Quarterly Biopsy Code Audit: Pull a random sample of 30 multi-biopsy encounters each quarter and verify that add-on codes and modifiers were applied wherever the clinical documentation supported them. Identify patterns of missed add-ons or modifier omissions before they compound into systemic revenue losses.

Why Dermatology Practices Are Outsourcing Biopsy Billing to Specialist Teams

Biopsy coding is not a simple lookup exercise it requires technique recognition, site documentation analysis, modifier logic, add-on code management, and payer-specific rule application on every multi-biopsy encounter. For high-volume dermatology practices, sustaining this level of coding accuracy in-house is genuinely difficult.

The Complexity Is Compounding With Volume

A solo dermatologist performing 10 biopsies per day generates 2,000–2,500 biopsy-related coding decisions per year. Each decision involves technique identification, site specificity confirmation, add-on code counting, modifier selection, and payer rule verification. At scale, in-house billing teams without specialty training default to single-code submission the path of least resistance that silently costs the practice tens of thousands annually.

Denial Management Requires Specialist Knowledge

When a biopsy claim is denied due to a modifier error or bundling issue, resolving it requires understanding exactly why the denial occurred and what documentation is needed to reverse it. Generic billing teams frequently write off low-to-moderate dollar biopsy denials rather than build the appeal accepting permanent revenue loss on claims that a specialist team would routinely recover.

Our Dermatology Billing Services Include Full Biopsy Code Review

Our expert dermatology billing solutions at MedCloudMD include pre-submission review of every biopsy encounter confirming technique-to-code alignment, add-on code completeness, modifier accuracy, and site documentation sufficiency before any claim reaches the payer. We also maintain current payer modifier matrices and NCCI edit databases so every submission uses the right code combination for the right payer.

🚀 Stop Leaving Biopsy Revenue Behind — Start Collecting What You've Earned

Every multi-biopsy encounter your practice performs is an opportunity to collect full, accurate reimbursement for each procedure performed. At MedCloudMD, our certified dermatology billing specialists review every biopsy claim at the code level ensuring add-ons are applied, modifiers are correct, documentation supports the submission, and nothing is left on the table.

We help dermatology practices across the U.S. recover $50,000–$150,000+ in annual biopsy-related revenue that was already earned but never collected through accurate code selection, documentation feedback, and proactive denial management.

📋  Schedule a Free Biopsy Billing Audit — Find Your Coding Revenue Gaps Today

Identify exactly where add-on codes and modifiers are missing in your biopsy claims

📈  Get a Dermatology Revenue Analysis — See What Accurate Biopsy Coding Recovers

Most practices identify $50,000–$150,000 in recoverable biopsy revenue in their first audit

📞  Talk to Our Dermatology Billing Experts — Zero Pressure, Maximum Insight

Certified biopsy coding specialists available for a free consultation today

🤝  Start Collecting Your Full Biopsy Reimbursement — This Month

medcloudmd.com/specialties/dermatology-billing-services

🏆  Why MedCloudMD — The Biopsy Coding Standard for Dermatology Practices

Biopsy Code Review on Every Multi-Site Encounter: Every claim with two or more biopsy codes is reviewed for add-on completeness, modifier accuracy, and documentation alignment before submission.

Dermatology-Exclusive Coding Team: Our coders understand dermatology biopsy techniques, NCCI edit rules, and payer-specific modifier policies for the 11102–11107 code family.

Current NCCI Edit and Add-On Code Exemption Knowledge: We track every CMS NCCI quarterly update ensuring add-on exemption rules and modifier requirements are always current across all biopsy code pairings.

Payer-Specific Biopsy Modifier Matrix: Updated semi-annually for every major commercial payer and Medicare contractor eliminating modifier-related denials from the billing workflow entirely.

Proactive Denial Management: Every biopsy denial is reviewed for recoverability and appealable denials are pursued to resolution, not written off.

Quarterly Biopsy Coding Performance Reports: We provide practice-level biopsy code distribution reports showing add-on utilization rates, denial rates by code pair, and identified undercoding patterns.

Provider Documentation Feedback Program: We work with your clinical team to improve anatomical specificity and technique documentation in biopsy procedure notes reducing denials at the source.

No Long-Term Contracts: We earn your business with measurable results every single month.

Explore Our Dermatology Billing Services: medcloudmd.com/specialties/dermatology-billing-services

© 2026 MedCloudMD  •  Skin Biopsy Coding Specialists  •  Dermatology Billing & Revenue Cycle Management